menu
    • menu

    Company profile for Selva Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. The company’s lead drug candidate, SLV213, is an orally available small molecule novel antiviral therapy with activity against a broad range of viruses that threaten global health, including SARS-CoV-2, the virus causing COVID-19. In addition, SLV213 has activity against Ebola and Nipah viruses a...
    Selva Therapeutics is a privately held biotechnology company dedicated to the development of therapeutics for infectious diseases. The company’s lead drug candidate, SLV213, is an orally available small molecule novel antiviral therapy with activity against a broad range of viruses that threaten global health, including SARS-CoV-2, the virus causing COVID-19. In addition, SLV213 has activity against Ebola and Nipah viruses and has completed preclinical development as a potential therapy against Chagas disease. Selva is headquartered in San Diego

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Selva TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Diego, CA
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://selvarx.com/selva/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/selva-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Selva's SLV213 Potently Inhibits Infection By the SARS-CoV-2 Omicron Variant
    Selva's SLV213 Potently Inhibits Infection By the SARS-CoV-2 Omicron Variant

    20 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220420005205/en

    BUSINESSWIRE
    20 Apr 2022
    Share Share
    Selva to Present Preclinical Data at ASV 2021 on SLV213
    Selva to Present Preclinical Data at ASV 2021 on SLV213

    19 Jul 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210719005210/en

    BUSINESSWIRE
    19 Jul 2021
    Share Share
    Selva’s Covid-19 drug shows activity against SARS-CoV-2 variants
    Selva’s Covid-19 drug shows activity against SARS-CoV-2 variants

    10 Jun 2021

    // CLINICAL TRAILS ARENA

    https://www.clinicaltrialsarena.com/news/selva-drug-activity-variants/

    CLINICAL TRAILS ARENA
    10 Jun 2021
    Share Share
    Selva Announces SLV213 has Broad Activity Against SARS-CoV-2 Variants of Concern
    Selva Announces SLV213 has Broad Activity Against SARS-CoV-2 Variants of Concern

    09 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210609005298/en/Selva-Announces-SLV213-a-Potential-Oral-COVID-19-Treatment-Has-Broad-Activity-Against-SARS-CoV-2-Variants-of-Concern

    BUSINESSWIRE
    09 Jun 2021
    Share Share
    Selva Announces Successful Completion of Phase 1 Clinical Study of SLV213
    Selva Announces Successful Completion of Phase 1 Clinical Study of SLV213

    02 Feb 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210202005408/en/Selva-Therapeutics-Announces-Successful-Completion-of-Phase-1-Clinical-Study-of-SLV213-a-Potential-Oral-Treatment-for-COVID-19

    BUSINESSWIRE
    02 Feb 2021
    Share Share
    Selva Announces First Dosing in Ph1 Clinical Study of SLV213
    Selva Announces First Dosing in Ph1 Clinical Study of SLV213

    12 Nov 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201112005296/en

    BUSINESSWIRE
    12 Nov 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search